X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.fiercepharma.com/pharma/x4-enters-commercial-fold-fda-approval-rare-disease-drug-xolremdi
https://www.globenewswire.com/news-release/2024/04/29/2871050/0/en/X4-Pharmaceuticals-Announces-FDA-Approval-of-XOLREMDI-mavorixafor-Capsules-First-Drug-Indicated-in-Patients-with-WHIM-Syndrome.html
https://www.prnewswire.com/news-releases/pantherx-rare-partnering-with-x4-pharmaceuticals-inc-for-the-distribution-of-xolremdi-mavorixafor-the-first-fda-approved-therapy-indicated-for-use-in-patients-with-whim-syndrome-302130332.html
https://www.globenewswire.com/news-release/2024/03/21/2850047/0/en/X4-Pharmaceuticals-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Provides-Corporate-Update.html
https://www.globenewswire.com//news-release/2023/12/09/2793437/0/en/X4-Pharmaceuticals-Announces-Presentation-of-Additional-Data-from-Mavorixafor-Phase-2-Trial-in-Chronic-Neutropenia-at-ASH-2023.html
https://www.globenewswire.com//news-release/2023/10/31/2770133/0/en/X4-Pharmaceuticals-Announces-FDA-Acceptance-with-Priority-Review-of-U-S-NDA-for-Mavorixafor-in-WHIM-Syndrome.html
https://www.globenewswire.com//news-release/2022/12/12/2571878/0/en/X4-Pharmaceuticals-Presentations-at-ASH-2022-Further-Highlight-Opportunity-for-Mavorixafor-in-the-Treatment-of-Chronic-Neutropenia.html
https://www.fiercebiotech.com/biotech/x4-fresh-layoffs-scores-phase-3-win-immune-deficiency-disorder-drug
https://www.globenewswire.com//news-release/2022/11/29/2564486/0/en/X4-Pharmaceuticals-Announces-Positive-Top-Line-Results-from-4WHIM-Global-Pivotal-Phase-3-Trial-of-Once-Daily-Oral-Mavorixafor-in-WHIM-Syndrome.html
https://www.globenewswire.com/news-release/2022/08/31/2507649/0/en/X4-Pharmaceuticals-to-Host-Investor-Webinar-Highlighting-New-Mavorixafor-Phase-1b-Data-in-Chronic-Neutropenia.html
https://www.globenewswire.com/news-release/2020/12/10/2143006/0/en/X4-Pharmaceuticals-Receives-Rare-Pediatric-Disease-Designation-from-FDA-for-Mavorixafor-for-the-Treatment-of-WHIM-Syndrome.html
https://www.globenewswire.com/news-release/2020/06/12/2047262/0/en/Autolus-Therapeutics-presents-AUTO1-and-AUTO3-data-at-the-2020-EHA25-Virtual-Congress.html
https://xconomy.com/boston/2018/11/27/x4-pharma-heads-to-nasdaq-via-reverse-merger-with-arsanis/
http://www.x4pharma.com/news/x4-pharmaceuticals-secures-27-million-series-b-financing/
Market Place
Share 
